A recent study reveals that an antibiotic used for liver disease patients may increase their risk of contracting a dangerous superbug.
An international team of researchers has discovered that rifaximin, a commonly prescribed antibiotic for liver disease patients, is contributing to the global rise of a highly resistant strain of vancomycin-resistant Enterococcus faecium (VRE). This superbug, which frequently causes severe infections in hospitalized patients, is becoming increasingly difficult to treat.
The study, published in Nature, reveals that rifaximin use is accelerating resistance to daptomycin—one of the last remaining effective antibiotics against VRE infections.
Led by scientists from the University of Melbourne’s Peter Doherty Institute for Infection and Immunity (Doherty Institute) and Austin Health, the research underscores the urgent need for a more comprehensive understanding of the unintended consequences of antibiotic use. It highlights the critical importance of responsible antibiotic prescribing to mitigate the spread of antimicrobial resistance.
Their findings reinforce the recent political declaration of the UN General Assembly High-Level Meeting on Antimicrobial Resistance (26 Sept 2024), where world leaders committed to decisive action on antimicrobial resistance, including reducing the estimated 4.95 million AMR-associated human deaths annually by 10 per cent by 2030.
How Rifaximin Promotes Antibiotic Resistance
The eight-year study drew on several disciplines, including molecular microbiology, bioinformatics and clinical science. Using large-scale genomics – the study of an organism’s DNA makeup – the scientists were able to identify changes in the DNA of daptomycin-resistant VRE that were absent in susceptible strains. Subsequent laboratory experimentation and clinical studies showed that rifaximin use caused these changes and resulted in the emergence of daptomycin-resistant VRE.
The University of Melbourne’s Dr Glen Carter, a Senior Research Fellow at the Doherty Institute and senior author of the study, said the research challenges the long-held belief that rifaximin poses a ‘low risk’ for causing antibiotic resistance.
“We’ve shown that rifaximin makes VRE resistant to daptomycin in a way that has not been seen before,” Dr Carter said.
“It is also of concern that these daptomycin-resistant VRE might be transmitted to other patients in the hospital; a hypothesis that we are presently investigating.”
A “Supercharged” Resistance Mechanism
The University of Melbourne’s Dr Adrianna Turner, a Research Officer at the Doherty Institute and first author of the study, said rifaximin triggers specific changes in an enzyme called RNA Polymerase within the bacteria. These changes “upregulate” a previously unknown gene cluster (prdRAB) leading to alterations in the VRE cell membrane and causing cross-resistance to daptomycin.
“When bacteria become resistant to an antibiotic, it’s a bit like gaining a new ability in a video game, like super-speed. But when exposed to rifaximin, the VRE bacteria don’t just get one boost – they gain multiple abilities, like super-speed and super-strength, allowing them to easily defeat even the final boss, which in this case is the antibiotic daptomycin,” Dr Turner said.
“In other words, rifaximin doesn’t just make bacteria resistant to one antibiotic; it can make them resistant to others, including critical last-resort antibiotics like daptomycin.”
Associate Professor Jason Kwong, Infectious Diseases Physician at Austin Health and lead investigator of the clinical studies, emphasized two critical implications of the findings.
“Firstly, clinicians must exercise caution when treating VRE infections in patients who have been taking rifaximin, since daptomycin’s efficacy may be compromised, necessitating laboratory verification before use,” Associate Professor Kwong said.
“Secondly, the findings underscore the importance of regulatory bodies considering ‘off-target and cross class’ effects when approving new drugs. For antibiotics, this means understanding whether exposure to one agent, like rifaximin, could induce resistance against other antibiotics – even those that work differently.
“Rifaximin is still a very effective medication when used appropriately and patients with advanced liver disease who are currently taking it should continue to do so. But we need to understand the implications going forward both when treating individual patients and from a public health perspective.”
The University of Melbourne’s Dr Claire Gorrie, a senior bioinformatician from the Doherty Institute and co-senior author, said the research highlights how cutting-edge technologies, combined with interdisciplinary collaboration, can uncover exactly how and why bacteria develop resistance to antibiotics – even those they’ve never encountered.
“These insights are crucial for developing smarter, more sustainable strategies for antibiotic use, especially as these life-saving drugs become an increasingly precious resource,” Dr Gorrie said.
Professor Benjamin Howden, the Director of the Microbiological Diagnostic Unit Public Health Laboratory at the Doherty Institute and an Infectious Diseases Physician at Austin Health, whose laboratory led the project, said the research will help ensure daptomycin remains an effective antibiotic for treating severe VRE infections in hospitals in Australia and around the world, particularly in the most vulnerable patients.
“Our findings highlight the critical need for effective genomics-based surveillance to detect emerging antimicrobial resistance. They also underscore the importance of judicious antibiotic use to safeguard vital last-resort treatments like daptomycin,” Professor Howden concluded.
Reference: “Rifaximin prophylaxis causes resistance to the last-resort antibiotic daptomycin” by Adrianna M. Turner, Lucy Li, Ian R. Monk, Jean Y. H. Lee, Danielle J. Ingle, Stephanie Portelli, Norelle L. Sherry, Nicole Isles, Torsten Seemann, Liam K. Sharkey, Calum J. Walsh, Gavin E. Reid, Shuai Nie, Bart A. Eijkelkamp, Natasha E. Holmes, Brennan Collis, Sara Vogrin, Andreas Hiergeist, Daniela Weber, Andre Gessner, Ernst Holler, David B. Ascher, Sebastian Duchene, Nichollas E. Scott, Timothy P. Stinear, Jason C. Kwong, Claire L. Gorrie, Benjamin P. Howden and Glen P. Carter, 23 October 2024, Nature.
DOI: 10.1038/s41586-024-08095-4
The team’s main collaborators were Bio21 Molecular Science and Biotechnology Institute; University Medical Center, Regensburg, Germany; The University of Queensland; and Flinders University, Adelaide.
The study was funded by the National Health and Medical Research Council.
News
Scientists Sound Alarm: “Safe” Antibiotic Has Led to an Almost Untreatable Superbug
A recent study reveals that an antibiotic used for liver disease patients may increase their risk of contracting a dangerous superbug. An international team of researchers has discovered that rifaximin, a commonly prescribed antibiotic [...]
Scientists Discover Natural Compound That Stops Cancer Progression
A discovery led by OHSU was made possible by years of study conducted by University of Portland undergraduates. Scientists have discovered a natural compound that can halt a key process involved in the progression [...]
Scientists Just Discovered an RNA That Repairs DNA Damage – And It’s a Game-Changer
Our DNA is constantly under threat — from cell division errors to external factors like sunlight and smoking. Fortunately, cells have intricate repair mechanisms to counteract this damage. Scientists have uncovered a surprising role played by [...]
What Scientists Just Discovered About COVID-19’s Hidden Death Toll
COVID-19 didn’t just claim lives directly—it reshaped mortality patterns worldwide. A major international study found that life expectancy plummeted across most of the 24 analyzed countries, with additional deaths from cardiovascular disease, substance abuse, and mental [...]
Self-Propelled Nanoparticles Improve Immunotherapy for Non-Invasive Bladder Cancer
A study led by Pohang University of Science and Technology (POSTECH) and the Institute for Bioengineering of Catalonia (IBEC) in South Korea details the creation of urea-powered nanomotors that enhance immunotherapy for bladder cancer. The nanomotors [...]
Scientists Develop New System That Produces Drinking Water From Thin Air
UT Austin researchers have developed a biodegradable, biomass-based hydrogel that efficiently extracts drinkable water from the air, offering a scalable, sustainable solution for water access in off-grid communities, emergency relief, and agriculture. Discarded food [...]
AI Unveils Hidden Nanoparticles – A Breakthrough in Early Disease Detection
Deep Nanometry (DNM) is an innovative technique combining high-speed optical detection with AI-driven noise reduction, allowing researchers to find rare nanoparticles like extracellular vesicles (EVs). Since EVs play a role in disease detection, DNM [...]
Inhalable nanoparticles could help treat chronic lung disease
Nanoparticles designed to release antibiotics deep inside the lungs reduced inflammation and improved lung function in mice with symptoms of chronic obstructive pulmonary disease By Grace Wade Delivering medication to the lungs with inhalable nanoparticles [...]
New MRI Study Uncovers Hidden Lung Abnormalities in Children With Long COVID
Long COVID is more than just lingering symptoms—it may have a hidden biological basis that standard medical tests fail to detect. A groundbreaking study using advanced MRI technology has uncovered significant lung abnormalities in [...]
AI Struggles with Abstract Thought: Study Reveals GPT-4’s Limits
While GPT-4 performs well in structured reasoning tasks, a new study shows that its ability to adapt to variations is weak—suggesting AI still lacks true abstract understanding and flexibility in decision-making. Artificial Intelligence (AI), [...]
Turning Off Nerve Signals: Scientists Develop Promising New Pancreatic Cancer Treatment
Pancreatic cancer reprograms nerve cells to fuel its growth, but blocking these connections can shrink tumors and boost treatment effectiveness. Pancreatic cancer is closely linked to the nervous system, according to researchers from the [...]
New human antibody shows promise for Ebola virus treatment
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics. [...]
Early Alzheimer’s Detection Test – Years Before Symptoms Appear
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving early Alzheimer’s diagnosis. Unlike amyloid-beta, tau neurofibrillary tangles are directly linked to cognitive decline. Years [...]
New mpox variant can spread rapidly across borders
International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly. The mpox virus [...]
How far would you trust AI to make important decisions?
From tailored Netflix recommendations to personalized Facebook feeds, artificial intelligence (AI) adeptly serves content that matches our preferences and past behaviors. But while a restaurant tip or two is handy, how comfortable would you [...]
Can AI Really Think? Research Reveals Gaps in Logical Execution
While AI models can break down problems into structured steps, new research reveals they still fail at basic arithmetic and fact-checking—raising questions about their true reasoning abilities. Large Language Models (LLMs) have become indispensable [...]
